Patty and Mark Loeffler, both 66, live active lives in Rancho Mirage, California. They are enthusiastic hikers and golfers, and they love to travel — especially to visit their seven...

Kevin O’Connor Many patients who come to City of Hope have never heard of the institution, never before set foot on the Duarte campus. The same cannot be said of Kevin O’Connor...

CONTACT-03 trial finds increased toxicity without clinical benefit in patients with advanced kidney cancer who received additional checkpoint inhibitor therapy after disease progression CONTACT Letisia Marquez 626-476-7593 lemarquez@coh.org LOS ANGELES...

With our clinical care, research and production facilities all on one campus, City of Hope has one of the most comprehensive CAR T programs worldwide. Our researchers and physicians are...

Usually we write about successful trials that introduce new, advanced treatments. This article, though, is about a trial that failed — but a failure that was so significant, it was...

Rama Natarajan, Ph.D., the National Business Products Industry Professor in Diabetes Research, first joined City of Hope in 1990 as an assistant research scientist. Soon after, she identified the role of...

City of Hope and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live...

 CONTACTCity of HopeZen Vuong626-409-9367zvuong@coh.org CONTACT for OselMichelle LinnBioscribe774-696-3803michelle@bioscribe.com Additional Phase 1 clinical trial of CBM588 plus immune checkpoint and...

City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic profiling that improve health...

In a clinical trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer — findings...